MarketCap
Facebook
X
Telegram
iBio Total Shareholders Equity | IBIO
Annual Total Shareholders Equity iBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.7 M | 14.9 M | 21.3 M | 15.4 M | 63.5 M | 109 M | 56.6 M | 2.46 M | 16.2 M | 8.91 M | 9.94 M | 11.2 M | 6.1 M | 5.07 M | 6.17 M | 196 K | 1.08 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | 196 K | 25.5 M |
Quarterly Total Shareholders Equity iBio
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.3 M | 77.5 M | 56.6 M | 56 M | 56.6 M | 56 M | 14.9 M | 11.4 M | 13.9 M | 17.8 M | 21.3 M | 24.9 M | 9.2 M | 13.2 M | 15.4 M | 17.4 M | 18.8 M | 48.4 M | 63.5 M | 79.4 M | 90.6 M | 101 M | 109 M | 109 M | 107 M | 80.1 M | 56.6 M | 56.6 M | -511 K | -1.93 M | 2.46 M | 2.46 M | 11.1 M | 13 M | 16.2 M | 16.2 M | 7.81 M | 6.29 M | 8.91 M | 8.91 M | 4.15 M | 7.14 M | 9.94 M | 9.94 M | 7.88 M | 9.81 M | 11.2 M | 11.2 M | 9.57 M | 5.44 M | 6.1 M | 6.1 M | 7.95 M | 5.68 M | 5.07 M | 5.07 M | 3.72 M | 4.57 M | 6.17 M | 6.17 M | 305 K | 886 K | 196 K | 197 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | -1.93 M | 25.6 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
-3.27 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Aclaris Therapeutics
ACRS
|
103 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-186 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
357 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-4.99 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
78.8 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
122 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
112 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
477 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-14.5 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
401 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
52.4 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
222 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
8.15 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
27.1 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
51.8 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
35.4 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
5.4 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
-46.8 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
51.2 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
93.1 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
48.2 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-6.6 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
1.15 B | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
159 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
442 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
10.6 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
87.6 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
1.25 B | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
31.8 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
-66.7 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
30.7 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
27.3 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
18.7 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-45.3 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
997 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
3.51 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
2.4 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
15.7 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-6.78 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
8.35 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
60.5 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
6.12 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
30.1 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
46.8 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
98.3 M | - | 1.02 % | $ 90.8 M | Britain |